PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study: Anti-obesity medications could be sold for lower prices

Change in cost may improve affordability, access to treatment

2023-04-14
(Press-News.org) ROCKVILLE, Md.—New research shows that several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs, according to a new study in Obesity, The Obesity Society’s (TOS) flagship journal.

“Access to medicine is a fundamental element of the human right to health. While the obesity pandemic grows, especially amongst low-income communities, effective medical treatments remain inaccessible for millions in need. Our study highlights the inequality in pricing that exists for effective anti-obesity medications, which are largely unaffordable in most countries. However, we show that these drugs can actually be produced and sold profitably for low prices. A public health approach that prioritizes improving access to medications should be adopted, instead of allowing companies to maximize profits,” said Jacob Levi, Intensive Care Medicine, Royal Free Hospital NHS Trust, London, United Kingdom. Levi is the corresponding author of the study.

Experts explain that the increasing recognition that diet and exercise alone is unlikely to result in sustained weight loss had led to renewed interest in medication to supplement lifestyle changes. Randomized controlled trials have demonstrated positive results with oral and injectable medications. However, these medications remain prohibitively expensive in most countries. Such high prices make it challenging for millions of people to afford the medications and obtain access to treatment.

“It would be great if everyone had affordable access to all medicines that might improve their health. Yet that is simply not possible, nor will it ever be. What is truly needed is a better way to ration the health care dollars currently available in efforts to maximize population health. That is the challenge ahead not just for anti-obesity medications but for all treatments,” said Eric A. Finkelstein, professor, Duke-NUS Medical School, Singapore, in a commentary about the study.

On the other hand, the authors have called for a public health based approach to obesity management similar to that used with other diseases. Andrew Hill, Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom, supervising author of the study, commented, "Worldwide, more people are dying from diabetes and clinical obesity than HIV, tuberculosis and malaria combined now. Millions of lives have been saved by treating infectious diseases at low cost in poor countries. Now we need to repeat this medical success story, with mass treatment of diabetes and clinical obesity at low prices. Pharmaceutical companies have an ethical responsibility to make their new treatments for diabetes and obesity available for anyone in need, in any country."

The study’s authors searched national drug price databases and collected information on six medications: orlistat, naltrexone/bupropion, topiramate/phentermine, liraglutide, semaglutide and tirzepatide across a range of 16 low-, middle- and high-income countries. In each country, researchers assessed multiple online national price databases and selected the lowest available price from each of the sources. Medications selected were chosen because they are proven effective and because they illustrate a range of different monotherapies, combination tablets and injectable treatments.

Estimated minimum prices (EMPs) for anti-obesity medications were calculated using established methodology using active pharmaceutical ingredients from the Panjiva database. EMPs were calculated per 30-day course and include costs of active pharmaceutical ingredients, excipients, formulation, taxation and 10% profit margin.

Results revealed that national prices of oral and injectable anti-obesity medications were significantly higher than calculated EMPs.

Oral Medications:

Orlistat: Prices for a 30-day course of treatment were greater than $100 in the United States and less than $1 in Vietnam. The calculated EMP from export API data was approximately $7 per 30-day course. Naltrexone/bupropion: Costs for naltrexone/bupropion combination tablets range from $326 in the United States to $56 in South Africa compared with an EMP of $55 per 30-day course. Topiramate/phentermine: Price data was only available in the United States since the medication is not licensed for use for weight loss in several countries because of safety concerns. Prices in the United States ranged from $120 to $199 per course compared with the EMP of the combination tablets at $5. Prices were also searched separately of topiramate and phentermine and combined with available data together from the United States, South Africa and Kenya. EMP’s for each drug individually were $0.86 for topiramate and $0.53 for phentermine (total of $1.39 per course) based on API export data. Injectable Medications:

Liraglutide: Injectable anti-diabetic and weight loss agent liraglutide costs $1,418 in the United States and $252 in Norway. The EMP per 30-day course was $50. Researchers note that this price was calculated assuming the most efficient concentration and dosage of available pens for injection. Semaglutide: National price data for subcutaneous semaglutide were all higher than EMPs ranging from $804 in the United States to $95 in Turkey. The EMP of subcutaneous semaglutide was calculated to be approximately $40 per 30-day course. Tirzepatide: National price data was only available in the United States, where the medication was recently licensed for use in type 2 diabetes by the Food and Drug Administration. The medication is not licensed for obesity alone. Prices for 30-day course ranged from about $715.56 to $1,100.70. Insufficient data existed in the database to calculate an EMP. The study’s authors note that EMPs are meant as realistic targets for competitive generic production rather than patented versions.

Caroline M. Apovian, MD, FTOS, co-director, Center for Weight Management and Wellness and professor of medicine at Harvard Medical School in Boston, Mass., commented, “Once we have shown that anti-obesity agents notably GLP-1 and combinations thereof lower cardiovascular risk, we can then demand universal insurance coverage of these agents. These agents used for obesity prior to the advent of type 2 diabetes, cardiovascular disease and other complications, have the power to reduce the cardiovascular burden and lower mortality worldwide.” Apovian was not associated with the research.

Other authors of the study include Junzheng Wang, Medical Sciences Office, Oxford University, Clinical Academic Graduate School, University of Oxford, Oxford, United Kingdom and Francois Venter, Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Venter has received support from the Bill and Melinda Gates Foundation, U.S. Agency for International Development, Uni-taid, SA Medical Research Council, Foundation for Innovative New Diagnostics, the Children’s Investment Fund Foundation, Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, Johnson & Johnson, Sanofi, Virology Education, SA HIV Clinicians Society and Dira Sengwe. The other authors declared no conflict of interest.

Funding for this study was provided by the Make Medicines Affordable/International Treatment Preparedness Coalition,  grant number  ITPC-MV_2020,https://makemedicinesaffordable.org/about/, and National Heart, Lung, and Blood Institute of the National Institutes of Health under award number UG3HL156388.

The study, titled “Estimated Minimum Prices and Lowest Available National Prices for Anti-obesity Medications: Improving Affordability and Access to Treatment,” is online and will be published in the print issue of Obesity in May 2023.

#  #  #

The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects. Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity. For more information, visit www.obesity.org.

END



ELSE PRESS RELEASES FROM THIS DATE:

Offering medications for opioid addiction to incarcerated individuals leads to decrease in overdose deaths

2023-04-14
BOSTON – New research from Boston Medical Center concluded that offering medications to treat opioid addiction in jails and prisons leads to a decrease in overdose deaths. Published in JAMA Network Open, the study also found that treating opioid addiction during incarceration is cost-effective in terms of healthcare costs, incarceration costs, and deaths avoided. Overdoses kill more than 100,000 people per year in America and this number continues to increase every year. People with addiction are more likely to be incarcerated than treated, with those from communities of color who use drugs more likely to be incarcerated than ...

SIAM Conference on Financial Mathematics and Engineering (FM23)

2023-04-14
The objective of the Activity Group on Financial Mathematics and Engineering is to advance fundamental research and implementation of practices in financial engineering, computation, and operations. The group aims at fostering collaborations among applied mathematicians, applied probabilists, statisticians, computer and data scientists, economists, as well as industry practitioners. The conference will expose state-of-art mathematical and computational tools in quantitative finance, including its uses in the public and private sector. The activity group promotes and supports the development of financial mathematics and engineering as an academic discipline. END ...

Ambrosia beetles can recognise their food fungi by their scents

Ambrosia beetles can recognise their food fungi by their scents
2023-04-14
Certain ambrosia beetles species engage in active agriculture. As social communities, they breed and care for food fungi in the wood of trees and ensure that so-called weed fungi spread less. Researchers led by Prof. Dr. Peter Biedermann, professor of Forest Entomology and Forest Protection at the University of Freiburg, now demonstrate for the first time that ambrosia beetles can distinguish between different species of fungi by their scents. "The results can contribute to a better understanding of why beetles selectively colonise trees with conspecifics and how ...

Study snapshot: Following the letter of the law: 2020–2021 retention outcomes under Michigan’s Read by Grade Three Law

2023-04-14
Study: "Following the Letter of the Law: 2020–2021 Retention Outcomes Under Michigan’s Read by Grade Three Law" Authors: Andrew Niel Utter (Michigan State University), John Westall (Michigan State University), Katharine O. Strunk (Michigan State University) Embargoed until: 12:01 a.m. CT Friday, April 14 This study will be presented at the place-based component of the 2023 Annual Meeting of the American Educational Research Association.  Session: Minding the Gap in Accountability Policy Implementation Date/Time: Friday, April 14, 2:50 p.m. – 4:20 p.m. CT Main Findings: Under Michigan’s “Read by Grade ...

The ACMG publishes statement on clinical, technical and environmental biases influencing equitable access to clinical genetics/genomics testing

2023-04-14
With the goal of fostering awareness and identifying strategies to reduce bias within the medical genetics field and to improve health equity, members of the ACMG’s Social, Ethical and Legal Issues (SELI) and Diversity, Equity and Inclusion (DEI) Committees collaborated to address factors in which bias can occur in clinical genetic testing in a just-published statement, “Clinical, technical, and environmental biases influencing equitable access to clinical genetics/genomics testing: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG)”. This is the first joint statement of the ACMG’s ...

Improving community outreach and engagement

Improving community outreach and engagement
2023-04-14
As researchers continue to make advances in new cancer prevention and treatment methods, it will not have much impact if the community is unaware and not engaged. For this reason, community outreach and engagement (COE) efforts are an important pillar of the University of Cincinnati Cancer Center’s mission. Cancer Center researchers will present research abstracts on several COE initiatives at the American Association for Cancer Research Annual Meeting 2023, held in Orlando, Florida, April 14-19. Encouraging ...

Healing the unhealable: New approach helps bones mend themselves

Healing the unhealable: New approach helps bones mend themselves
2023-04-14
Young babies and newborn mice can naturally heal damage to the bones that form the top of the skull, but this ability is lost in adults. In a new study published in Proceedings of the National Academy of Sciences, University of Pittsburgh researchers developed a novel approach that promoted bone regeneration in mice without implantation of bone tissue or biomaterials. The technique uses a device similar to an orthodontic wire used to realign teeth to carefully stretch the skull along its sutures, activating ...

Scientists narrow down pool of potential height genes

Scientists narrow down pool of potential height genes
2023-04-14
When it comes to height, our fate is sealed along with our growth plates—cartilage near the ends of bones that hardens as a child develops. Research publishing April 14 in the journal Cell Genomics shows that cells in these plates determine the length and shape of our bones and can hint at our stature. The study identified potential "height genes" and found that genetic changes affecting cartilage cell maturation may strongly influence adult height. "The study is really understanding ...

Finding the dream team to beat the heat

Finding the dream team to beat the heat
2023-04-14
Associate Professor Jonathan Boreyko leads a team at Virginia Tech that has built a strong portfolio of work with ice and water, exploring the possibilities for de-icing planes, building novel water harvesting devices, and creating snow globes out of bubbles. This familiarity with water has given the team a strong sense of its behavior in different states, leading to a new project that shows how ice quenches heat in comparison to water. The findings were published in Chem on April 14. Mojtaba Edalatpour and master’s student Camryn ...

Analysis of health and prescription data suggests chronic health conditions in U.S. incarcerated people may be severely undertreated

2023-04-14
Chronic conditions such as type 2 diabetes, asthma, HIV infection, and mental illness may be greatly undertreated in the U.S. jail and prison population, suggests a new study from researchers at the Johns Hopkins Bloomberg School of Public Health. For their analysis, the researchers used national health survey data covering 2018 to 2020 to estimate rates of chronic conditions among recently incarcerated people, and a commercial prescription database to estimate the distribution of medication treatments to the jail and prison population. Their analysis suggests ...

LAST 30 PRESS RELEASES:

New test helps doctors predict a dangerous side effect of cancer treatment

UC Study: Long sentences for juveniles make reentry into society more difficult

Death by feral cat: DNA shows cats to be culprits in killing of native animals

Plant Physiology is Searching for its Next Editor-in-Chief

Clothes dryers and the bottom line: Switching to air drying can save hundreds

New insights into tRNA-derived small RNAs offer hope for digestive tract disease diagnosis and treatment

Emotive marketing for sustainable consumption?

Prostate cancer is not a death knell, study shows

Unveiling the role of tumor-infiltrating immune cells in endometrial carcinoma

Traditional Chinese medicine unlocks new potential in treating diseases through ferroptosis regulation

MSU study pinpoints the impact of prenatal stress across 27 weeks of pregnancy

Biochemist’s impact on science and students honored

ELF4: A key transcription factor shaping immunity and cancer progression

Updated chronic kidney disease management guidelines recommend SGLT2 inhibitors regardless of diabetes or kidney disease type

New research explores how AI can build trust in knowledge work

Compound found in common herbs inspires potential anti-inflammatory drug for Alzheimer’s disease

Inhaled COVID vaccine begins recruitment for phase-2 human trials

What’s in a label? It’s different for boys vs. girls, new study of parents finds

Genes combined with immune response to Epstein-Barr virus increase MS risk

Proximity and prejudice: Gay discrimination in the gig economy

New paper suggests cold temperatures trigger shapeshifting proteins

Reproductive justice–driven pregnancy interventions can improve mental health

Intranasal herpes infection may produce neurobehavioral symptoms, UIC study finds

Developing treatment strategies for an understudied bladder disease

Investigating how decision-making and behavioral control develop

Rutgers researchers revive decades-old pregnancy cohort with modern scientific potential

Rising CO2 likely to speed decrease in ‘space sustainability’ 

Study: Climate change will reduce the number of satellites that can safely orbit in space

Mysterious phenomenon at center of galaxy could reveal new kind of dark matter

Unlocking the secrets of phase transitions in quantum hardware

[Press-News.org] Study: Anti-obesity medications could be sold for lower prices
Change in cost may improve affordability, access to treatment